Want to see CMMB full AI Analyst Report?
CMMB Stock Chart & Stats
$1.36
$0.04(2.94%)
At close: 4:00 PM EDT
$1.36
$0.04(2.94%)
Day’s Range― - ―
52-Week Range$1.35 - $4.54
Previous CloseN/A
Volume17.83K
Average Volume (3M)207.96K
Market Cap
$10.22M
Enterprise Value$4.48
Total Cash (Recent Filing)$8.04M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Aug 07, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding7,192,266
10 Day Avg. Volume363,095
30 Day Avg. Volume207,955
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.85
Price to Sales (P/S)0.00
P/FCF Ratio-0.94
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.00Price Target Upside1002.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet StrengthVery low or negligible debt materially reduces bankruptcy and interest-rate risk, giving management durable financial flexibility to prioritize R&D and partnership negotiations. This structural balance-sheet strength supports sustained operations through financing cycles and improves negotiating leverage with collaborators.
Improving Loss And Cash-burn TrendsReported improvement in 2025 operating losses and burn signals tightening expense discipline and more efficient capital use. Sustained improvement in burn rates can extend runway, reduce near-term financing frequency, and increase attractiveness to partners or acquirers over the next several quarters.
Strategic Merger And Committed FinancingThe planned stock-for-stock merger and $30M committed financing represent a structural business shift: adds Scipher's precision-medicine revenues and AI capabilities, diversifies beyond a single asset, and materially extends funding runway, improving execution prospects for nebokitug and pipeline development.
Bears Say
Pre-revenue, Persistent Operating LossesA multi-year pre-revenue profile and recurrent net losses mean the business lacks self-sustaining product cash flow. Long-term value creation depends entirely on successful clinical outcomes, approvals, or partner deals, making the company structurally exposed to clinical and regulatory execution risk.
Substantial Cash Burn And Financing DependenceConsistent negative operating and free cash flow leaves the company reliant on external capital or partner proceeds. Even with improvement in 2025, ongoing burn creates vulnerability to capital-market dislocations and forces dilution or accelerated dealmaking when funding is required.
Dilution And Reduced Shareholder Influence From Transaction And Capital ActionsThe merger structure and issued contingent-value rights imply meaningful dilution and reduced governance influence for Chemomab holders. Coupled with an authorized capital increase approved by shareholders, these structural moves raise the risk of future dilution and limit liquidity/transferability of contingent upside for existing investors.
Chemomab Therapeutics News
CMMB FAQ
What was Chemomab Therapeutics’s price range in the past 12 months?
Chemomab Therapeutics lowest stock price was $1.35 and its highest was $4.54 in the past 12 months.
What is Chemomab Therapeutics’s market cap?
Chemomab Therapeutics’s market cap is $10.22M.
When is Chemomab Therapeutics’s upcoming earnings report date?
Chemomab Therapeutics’s upcoming earnings report date is Aug 07, 2026 which is in 9 days.
How were Chemomab Therapeutics’s earnings last quarter?
Chemomab Therapeutics released its earnings results on May 14, 2026. The company reported -$0.003 earnings per share for the quarter, missing the consensus estimate of $0 by -$0.003.
Is Chemomab Therapeutics overvalued?
According to Wall Street analysts Chemomab Therapeutics’s price is currently Undervalued.
Does Chemomab Therapeutics pay dividends?
Chemomab Therapeutics does not currently pay dividends.
What is Chemomab Therapeutics’s EPS estimate?
Chemomab Therapeutics’s EPS estimate is 0.
How many shares outstanding does Chemomab Therapeutics have?
Chemomab Therapeutics has 7,192,266 shares outstanding.
What happened to Chemomab Therapeutics’s price movement after its last earnings report?
Chemomab Therapeutics reported an EPS of -$0.003 in its last earnings report, missing expectations of $0. Following the earnings report the stock price went down -2.299%.
Which hedge fund is a major shareholder of Chemomab Therapeutics?
Currently, no hedge funds are holding shares in CMMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chemomab Therapeutics
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
CMMB Stock 12 Month Forecast
Average Price Target
$15.00
▲(1002.94% Upside)